Will Biopharma Regulators Maintain Their Accelerated Pace?

Regulators and biopharmas alike have been working on accelerated timelines in the development and production of vaccines, many of which have benefitted from Emergency Use Authorization. Can that pace be maintained post-pandemic? If it can, will it? In this segment of our recent BioProcess Online Live! event Manufacturing Vaccines On COVID's Coattails, Christina Yi, Chief Operating Officer at Vaxxinity, vaccine commercialization expert Kimberly Murphy, and Valneva Chief Medical Officer Dr. Juan Carlos Jaramillo posit on progress, what will stick as we return to something closer to "normal," and why improvement of tech infrastructure is key to speeding vaccines and therapies to patients in need.

View the full presentation on-demand here.